In vivo, the inhibition of tumor growth coincided with a significant decrease in proliferation, and a reduction in the expression of growth factors known to drive malignant tumor progression phenotypes including angiogenesis such as VEGF and hyperproliferation such as, PDGF, FGF, EGFR, and HGRF. This evidence concerns the gene VEGFA and neoplasm.